secwatch.observer — SEC 8-K summary
======================================

Issuer:     CG Oncology, Inc. (CGON)
CIK:        0001991792
Form:       8-K
Filed at:   2026-05-08T23:59:59+00:00
Accession:  0001193125-26-213440
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CG Oncology Q1 net loss widens to $60.2M; BLA submission on track for Q4 2026
-----------------------------------------------------------------------------

- Net loss of $60.2M ($0.71 per share) vs $34.5M ($0.45) in Q1 2025.
- Cash, cash equivalents & marketable securities $1.1B as of March 31, 2026; includes $391.4M from ATM sales.
- BLA for cretostimogene in HR BCG-unresponsive NMIBC expected to complete in Q4 2026 after FDA alignment.
- Phase 3 PIVOT-006 topline data in intermediate-risk NMIBC anticipated 1H 2026.
- Appointed Jim DeTore as CFO in April 2026; he brings 30+ years life sciences experience.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1991792/000119312526213440/0001193125-26-213440-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1991792/000119312526213440/ck0001991792-20260508.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-213440

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer